At Glooko, we’re the partner of choice for hospitals and health systems interested in solving the growing challenge of glycemic safety and diabetes management across care settings. That’s why we’re excited to meet with healthcare leaders at the American Diabetes Association’s 2026 Scientific Sessions from June 5 to 8 in New Orleans and share how we’re advancing comprehensive inpatient and outpatient diabetes care.
During the annual conference, we’ll showcase how we’re helping care teams simplify diabetes management across the care continuum, from inpatient glycemic management with the algorithm-driven EndoTool Glucose Management System to optimizing diabetes care in the clinic through the outpatient Glooko diabetes management platform.
Diabetes Connected Care Solutions with Native EHR Interoperability at Booth #1301
As a global digital health leader, we know the importance of clinical workflow optimization in both inpatient and outpatient settings.
Diabetes researchers, endocrinologists, physicians, nurses, dietitians, and certified diabetes care and education specialists who visit booth #1301 can learn how our diabetes connected care solutions bring diabetes and health data into existing clinical workflows via seamless EHR integration.
The native EHR interoperability of Glooko and EndoTool, both part of our software portfolio, help reduce data complexity, streamline decision-making, and give clinicians more time to focus on delivering high-quality patient care.
Don’t Miss our Product Theater Session on EHR Integrations
Glooko will host the ADA Product Theater Session: “The Connected Continuum: Reducing Clinician Burden Across Care Settings with EHR- Integrated Diabetes Data” from 3 to 3:45 p.m., CT, June 6, in Product Theater 2.
Join Glooko Chief Medical and Strategy Officer Mark Clements, MD, PhD, and a panel of clinical and operational leaders, including Ann & Robert H. Lurie Children’s Hospital of Chicago Chief Research Informatics Officer Juan Espinoza, MD, a global expert in EHR integration and Interoperability, Richie Torres, MSN, APRN-BC, an endocrinology nurse practitioner at Mount Sinai Hospital, and Glooko Senior Clinical Transformation Director Trisha Martinez, BSN, MBA, RN, for a discussion on how EHR-integrated diabetes data can help care teams work more efficiently across settings.
The panel will share real-world perspectives on how connected data workflows can help clinicians move from fragmented information to timely insights, supporting safer inpatient glycemic management, more efficient outpatient care, and better alignment across the care continuum.
Attendees will also be the first to receive a digital copy of the Glooko 2026 Annual Diabetes Report.
Supporting the Next Generation of Diabetes Technology Leaders
Glooko is proud to empower the next generation of endocrinology leaders. We’re thrilled to sponsor Interoperability of Diabetes Device Data into the EHR, an exclusive pre-conference session hosted by the Diabetes Technology Society on June 4 and 5, specifically designed for fellows and outpatient clinicians interested in digital health and connected care. The session, led by respected diabetes technology leaders, dives deep into the essentials of diabetes device interoperability, EHR integration and workflows, and remote interpretation and billing.
Experience Glooko and EndoTool at Booth #1301
Interested in seeing how our smarter EHR-integrated workflows can help your team reduce burden, simplify inpatient and outpatient diabetes data management, and deliver more connected care?
Schedule a demo of our diabetes and glycemic management software
EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool’s ability to use available patient information within the hospital’s electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.
This is not part of the 2026 Scientific Sessions as planned by the American Diabetes Association®. This content is neither sponsored nor endorsed by the American Diabetes Association®. This content does not qualify for continuing medical education (CME) credit.